Health Catalyst, Inc. 8-K

What Happened

• Health Catalyst, Inc. announced in an 8‑K that on January 20, 2026 the Board determined Kevin Freeman will cease serving as Chief Commercial Officer effective February 1, 2026.
• The company expects to enter a separation agreement that provides Mr. Freeman with the separation benefits under its Executive Severance Plan (as summarized in the company’s May 19, 2025 proxy), and then enter an independent contractor agreement for Mr. Freeman to serve as a senior advisor beginning February 2, 2026.
• The filing includes a standard forward‑looking statement cautioning that the agreements are anticipated but not guaranteed and subject to risks and uncertainties.

Key Details

• Board determination date: January 20, 2026.
• CCO role end date: February 1, 2026.
• Anticipated advisor start date: February 2, 2026 (via independent contractor agreement).
• Separation benefits referenced: those under Health Catalyst’s Executive Severance Plan (see Definitive Proxy Statement on Schedule 14A, filed May 19, 2025); benefits provided in exchange for a general release of claims.

Why It Matters

• A change in the chief commercial officer affects the company’s commercial leadership and go‑to‑market execution; investors should note the timing and the company’s plan to retain Mr. Freeman as a senior advisor to support transition.
• The separation agreement and any severance payments are governed by the company’s Executive Severance Plan and could have a modest near‑term compensation impact; the filing does not quantify costs.
• The filing does not announce a successor or give reasons for the change, so investors may watch subsequent disclosures (8‑K, press release, or earnings calls) for leadership succession details or any operational impact.